These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1673628)

  • 41. Metergoline as a lactation inhibitor.
    Caballero A; Palomo A; Molina CE; Albarrán FJ; Caballero A; Mena P
    J Reprod Med; 1982 Apr; 27(4):202-6. PubMed ID: 7097670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CV 205-502 treatment of macroprolactinomas.
    Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women.
    Cicinelli E; Cignarelli M; Petruzzi D; Matteo MG; Ruccia C; Schonauer LM
    J Endocrinol Invest; 1996; 19(7):427-32. PubMed ID: 8884536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of dihydroergocryptine on serum prolactin levels and milk secretion in puerperal women.
    Nappi C; Colace G; Di Carlo C; Affinito P; Ruotolo C; Montemagno R; Farace MJ; Mailland F; Di Renzo GF
    Gynecol Endocrinol; 1993 Jun; 7(2):129-33. PubMed ID: 8213227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Early and late inhibition of lactation using bromocriptine. A comparative study (author's transl)].
    Chef R; Meert B
    J Gynecol Obstet Biol Reprod (Paris); 1978; 7(5):1003-12. PubMed ID: 570200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502.
    Rasmussen C; Brownell J; Bergh T
    Acta Endocrinol (Copenh); 1991 Aug; 125(2):170-6. PubMed ID: 1680264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of bromocriptine versus breast binders as inhibitors of postpartum lactation.
    Shapiro AG; Thomas L
    South Med J; 1984 Jun; 77(6):719-21. PubMed ID: 6729548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test.
    Gaillard RC; Abeywickrama K; Brownell J; Muller AF
    J Clin Endocrinol Metab; 1989 Feb; 68(2):329-35. PubMed ID: 2563733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bromocriptine mesylate for prevention of postpartum lactation.
    Duchesne C; Leke R
    Obstet Gynecol; 1981 Apr; 57(4):464-7. PubMed ID: 7243095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abnormal prolactin levels and pituitary-gonadal axis in the puerperium.
    Andersen AN; Tabor A; Hertz JB; Schiøler V
    Obstet Gynecol; 1981 Jun; 57(6):725-9. PubMed ID: 7231824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Serum prolactin levels during inhibition of lactation with 2-brom-alpha-ergocryptin (CB 154) (author's transl)].
    Gerstner G; Mick R; Spona J
    Wien Klin Wochenschr; 1977 Oct; 89(19):664-7. PubMed ID: 910447
    [No Abstract]   [Full Text] [Related]  

  • 52. The treatment of puerperal lactation with bromocriptine.
    Cooke I; Foley M; Lenton E; Preston E; Millar D; Jenkins A; Obiekwe B; McNeilly A; Parsons J; Kennedy G
    Postgrad Med J; 1976; 52suppl 1():75-80. PubMed ID: 959129
    [No Abstract]   [Full Text] [Related]  

  • 53. [EGF binding site number of rat anterior pituitary is increased by chronic administration with dopaminergic agonist, CV 205-502].
    Birman P; Bai-Grenier F; Joubert D
    C R Acad Sci III; 1991; 312(6):241-5. PubMed ID: 1675150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationships between prolactin and follicle-stimulating hormone during early pregnancy and the puerperium.
    Khattab TY; Jequier AM
    J Endocrinol; 1978 Sep; 78(3):351-8. PubMed ID: 712295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of bromocriptine treatment during early pregnancy on postpartum maternal behaviors in rats.
    Price AK; Bridges RS
    Dev Psychobiol; 2014 Sep; 56(6):1431-7. PubMed ID: 24889499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of puerperal lactation by means of a single injection of bromocriptine retard.
    Valsamis J; Chavez H; Westelinck K; Haemers M; Francis G; L'Hermite M
    Eur J Obstet Gynecol Reprod Biol; 1987 May; 25(1):43-51. PubMed ID: 3595974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Value of cyclofenil in the inhibition of lactation. Efficacy compared to bromocriptine].
    Cingotti M; Magnin G
    Rev Fr Gynecol Obstet; 1986; 81(6-7):369-72. PubMed ID: 3094130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of lactation and season on plasma prolactin concentrations and response to bromocriptine during lactation in the Bennett's wallaby (Macropus rufogriseus rufogriseus).
    Curlewis JD; White AS; Loudon AS; McNeilly AS
    J Endocrinol; 1986 Jul; 110(1):59-66. PubMed ID: 3755462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stimulation of growth hormone release in man by the potent D2-dopamine agonist CV 205-502: comparison of responses to intravenous and oral administration.
    Miell JP; Pralong FP; Corder R; Gaillard RC
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1519-24. PubMed ID: 1977760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.